MENS
Jyong Biotech·NASDAQ
--
--(--)
--
--(--)
MENS fundamentals
During H1 2025, Jyong Biotech (MENS) reported revenue of --, a YoY change of 0.00%. Net income was -1.25M, a YoY change of 5.58%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | H1,2025 | TTM |
|---|
Start Date | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2025 | -- |
End Date | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Jun 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 2.40M -- | 1.21M -- | 2.83M +17.68% | 1.11M -8.57% | 2.80M -1.13% | 951.00K -14.25% | 816.00K -14.20% | -- -- |
Selling, General and Administrative Expenses | 845.00K -- | 532.00K -- | 1.54M +82.13% | 571.00K +7.33% | 1.73M +12.15% | 452.00K -20.84% | 449.00K -0.66% | -- -- |
Selling and Marketing Expenses | -- -- | -- -- | 47.00K -- | 22.00K -- | 47.00K -- | 21.00K -4.55% | 20.00K -4.76% | -- -- |
General and Administrative Expenses | -- -- | -- -- | 1.49M -- | 549.00K -- | 1.68M +12.53% | 431.00K -21.49% | 429.00K -0.46% | -- -- |
Research and Development Expenses | 1.56M -- | 681.00K -- | 1.29M -17.25% | 538.00K -21.00% | 1.07M -16.98% | 499.00K -7.25% | 367.00K -26.45% | -- -- |
Operating Income | -2.40M -- | -1.21M -- | -2.83M -17.68% | -1.11M +8.57% | -2.80M +1.13% | -951.00K +14.25% | -816.00K +14.20% | -- -- |
Non-Operating Income (Loss) | -1.79M -- | -727.00K -- | -3.80M -111.87% | -633.00K +12.93% | -1.60M +57.83% | -375.00K +40.76% | -436.00K -16.27% | -- -- |
Other Non-Operating Income (Loss) | -965.00K -- | -363.00K -- | -3.04M -215.13% | -276.00K +23.97% | -902.00K +70.34% | 67.00K +124.28% | -43.00K -164.18% | -- -- |
Net Interest Expense | 829.00K -- | 364.00K -- | 760.00K -8.32% | 357.00K -1.92% | 701.00K -7.76% | 442.00K +23.81% | 393.00K -11.09% | -- -- |
Interest Expense | 835.00K -- | 366.00K -- | 765.00K -8.38% | 359.00K -1.91% | 757.00K -1.05% | 448.00K +24.79% | 417.00K -6.92% | -- -- |
Interest Income | 6.00K -- | 2.00K -- | 5.00K -16.67% | 2.00K -- | 56.00K +1020.00% | 6.00K +200.00% | 24.00K +300.00% | -- -- |
Pretax Income From Continuing Operations | -4.20M -- | -1.94M -- | -6.63M -57.93% | -1.74M +10.21% | -4.40M +33.63% | -1.33M +23.88% | -1.25M +5.58% | -- -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- |
Net Income | -4.20M -- | -1.94M -- | -6.63M -57.93% | -1.74M +10.21% | -4.40M +33.63% | -1.33M +23.88% | -1.25M +5.58% | -- -- |
Net Income Attributable to Owners of the Company | -4.20M -- | -1.94M -- | -6.63M -57.93% | -1.74M +10.21% | -4.40M +33.63% | -1.33M +23.88% | -1.25M +5.58% | -- -- |
Net Income Attributable to Common Stockholders | -4.20M -- | -1.94M -- | -6.63M -57.93% | -1.74M +10.21% | -4.40M +33.63% | -1.33M +23.88% | -1.25M +5.58% | -- -- |
Other Comprehensive Income | 77.00K -- | 191.00K -- | 324.00K +320.78% | 124.00K -35.08% | -42.00K -112.96% | 473.00K +281.45% | -1.16M -345.03% | -- -- |
Total Comprehensive Income | -4.12M -- | -1.75M -- | -6.31M -53.02% | -1.62M +7.49% | -4.44M +29.56% | -853.00K +47.28% | -2.41M -182.65% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -4.12M -- | -1.75M -- | -6.31M -53.02% | -1.62M +7.49% | -4.44M +29.56% | -853.00K +47.28% | -2.41M -182.65% | -- -- |
Basic EPS | -0.06 -- | -0.03 -- | -0.09 -50.00% | -0.02 +33.33% | -0.06 +33.33% | -0.02 -- | -0.02 -- | -- -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -0.09 -- | -0.02 -- | -0.06 +33.33% | -0.02 -- | -0.02 -- | -- -- |
Diluted EPS | -0.06 -- | -0.03 -- | -0.09 -50.00% | -0.02 +33.33% | -0.06 +33.33% | -0.02 -- | -0.02 -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -0.09 -- | -0.02 -- | -0.06 +33.33% | -0.02 -- | -0.02 -- | -- -- |
You can ask Aime
What were the key takeaways from Jyong Biotech's earnings call?What guidance did Jyong Biotech's management provide for the next earnings period?What is Jyong Biotech's latest dividend and current dividend yield?What does Jyong Biotech do and what are its main business segments?What were the key takeaways from Jyong Biotech’s earnings call?What factors drove the changes in Jyong Biotech's revenue and profit?What is the revenue and EPS growth rate for Jyong Biotech year over year?Did Jyong Biotech beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
